相似文献
1
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Mar;27(3):928-931. doi: 10.3201/eid2703.204543. Epub 2020 Dec 22.
2
Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Jan;27(1):327-9. doi: 10.3201/eid2701.203515. Epub 2020 Oct 13.
3
Antibody Responses One Year after Mild SARS-CoV-2 Infection.
J Korean Med Sci. 2021 May 31;36(21):e157. doi: 10.3346/jkms.2021.36.e157.
4
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9. doi: 10.1016/j.cmi.2020.11.009. Epub 2020 Nov 20.
5
Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.
Emerg Infect Dis. 2021 Feb;27(2):663-666. doi: 10.3201/eid2702.204226.
6
Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.
Front Immunol. 2021 Aug 16;12:722027. doi: 10.3389/fimmu.2021.722027. eCollection 2021.
7
Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.
Emerg Infect Dis. 2020 Oct;26(10):2484-2487. doi: 10.3201/eid2610.202211. Epub 2020 Jun 24.
8
Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
Emerg Infect Dis. 2021 Feb;27(2):636-638. doi: 10.3201/eid2702.201960. Epub 2020 Dec 21.
9
SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6. doi: 10.1016/j.cmi.2021.05.008. Epub 2021 May 8.
10
Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
Emerg Infect Dis. 2021 Feb;27(2):628-631. doi: 10.3201/eid2702.204088.
引用本文的文献
1
Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients.
J Surg Res (Houst). 2023;6(4):348-363. doi: 10.26502/jsr.10020321. Epub 2023 Oct 18.
2
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.
Sci Rep. 2024 Jan 24;14(1):2091. doi: 10.1038/s41598-023-50338-3.
3
Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 Messenger Ribonucleic Acid Vaccines in Infected Individuals: A Systematic Review.
Malays J Med Sci. 2023 Aug;30(4):8-24. doi: 10.21315/mjms2023.30.4.2. Epub 2023 Aug 24.
4
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19.
Microorganisms. 2023 Aug 2;11(8):1985. doi: 10.3390/microorganisms11081985.
5
Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa.
Afr J Lab Med. 2023 Jun 29;12(1):2065. doi: 10.4102/ajlm.v12i1.2065. eCollection 2023.
6
Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.
Euro Surveill. 2023 May;28(21). doi: 10.2807/1560-7917.ES.2023.28.21.2200809.
7
Assessment of Reactivity to the Administration of the mRNA Vaccine after Six Months of Observation.
Vaccines (Basel). 2023 Feb 6;11(2):366. doi: 10.3390/vaccines11020366.
8
Persistence of IgG COVID-19 antibodies: A longitudinal analysis.
Front Public Health. 2023 Jan 10;10:1069898. doi: 10.3389/fpubh.2022.1069898. eCollection 2022.
9
Symptomatic and Asymptomatic SARS-CoV-2 Infection and Follow-up of Neutralizing Antibody Levels.
Biomed Environ Sci. 2022 Dec 20;35(12):1100-1105. doi: 10.3967/bes2022.139.
10
Attitudes and practices against COVID-19 vaccines in Turkiye.
North Clin Istanb. 2022 Oct 27;9(5):484-494. doi: 10.14744/nci.2022.82652. eCollection 2022.
本文引用的文献
1
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.
2
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
3
Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Jan;27(1):327-9. doi: 10.3201/eid2701.203515. Epub 2020 Oct 13.
4
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.
Lancet Infect Dis. 2020 Dec;20(12):1390-1400. doi: 10.1016/S1473-3099(20)30634-4. Epub 2020 Sep 23.
5
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
6
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
Nat Biotechnol. 2020 Sep;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z. Epub 2020 Jul 23.
7
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.
BMJ. 2020 Jul 1;370:m2516. doi: 10.1136/bmj.m2516.
8
Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.
Emerg Infect Dis. 2020 Oct;26(10):2484-2487. doi: 10.3201/eid2610.202211. Epub 2020 Jun 24.
9
Operating Protocols of a Community Treatment Center for Isolation of Patients with Coronavirus Disease, South Korea.
Emerg Infect Dis. 2020 Oct;26(10):2329-2337. doi: 10.3201/eid2610.201460. Epub 2020 Jun 22.
10
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
Zotero 插件